The Food and Drug Administration (FDA) has approved Enbumyst™, a nasal spray formulation of bumetanide, for the treatment of edema associated with congestive heart failure (CHF), and hepatic and renal disease, including nephrotic syndrome in adults. The approval of Enbumyst was supported by data from a clinical trial that compared the absorption and efficacy of intranasal bumetanide with oral and intravenous (IV) bumetanide in 68 healthy adults. Findings showed the effect of a 2 mg dose of Enbumyst on diuresis, natriuresis, and potassium urine excretion over 0 to 8 hours and 0 to 24 hours was similar to that of 2 mg bumetanide oral tablet and 2 mg bumetanide IV injection. Enbumyst is supplied in a unit-dose nasal spray containing bumetanide 0.5 mg per 0.1 mL. Patients should alternate between the right and left nostrils if the dose requires more than 1 nasal spray.